HOME >> MEDICINE >> NEWS
OTC statins: A bad decision for public health

This week's editorial raises concerns over the recent decision by the UK government to make the cholesterol-lowering drug simvastatin available over the counter (OTC) from July this year for people at moderate risk of cardiovascular disease.

The editorial comments: 'There are no trials of OTC statins for primary prevention of heart disease. There are no data on compliance with OTC statins, which for products that need to be taken daily longterm is a concern. Will those who buy simvastatin also stop smoking, lose weight, and do more exercise, or will they substitute drug use for lifestyle modification? Will pharmacists have the time to determine the individual's risk of coronary heart disease before selling the drug and also to give lifestyle advice? All these are unknowns, which is unfortunate for the UK public, who will be the guineapigs in this large-scale OTC experiment. Americans have escaped this role, with two applications for OTC statins (pravastatin 10 mg and lovastatin 10 mg) being rejected in 2000 because of insufficient evidence that either drug could be used safely and effectively in an OTC setting'.

Financial reasons are suggested as the driver behind the decision: 'In the absence of evidence of the overall mortality benefits of OTC simvastatin, it is difficult to avoid concluding that the motive behind the Government's decision is saving money. Statins are currently prescribed to about 1.8 million people in the UK, costing the NHS 700 million a year. With the NHS bill for statins predicted to be more than 2 billion a year by 2010, transferring costs to patients might seem timely. But privatising the prevention of heart disease will increase inequalities, with many unable to afford the likely 10-15 per month longterm. For the manufacturer, of course, the motive is clear. With simvastatin now off patent, creation of a new market (perhaps 8 million more people in the UK) will please shareholders'.

The editorial concludes: 'What i
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
20-May-2004


Page: 1 2

Related medicine news :

1. Teaching a less obvious medical skill -- Ethical decision-making
2. Balancing care decisions for gravely ill patients
3. How the stories of ordinary people could give them more say over planning decisions
4. Web-based tool to help clinicians make schizophrenia treatment decisions
5. Fair decisions more important when hospitals face crisis like SARS
6. Testosterone patch will test FDAs decision making
7. Aiding decision making for Baby Charlotte and Baby Luke
8. Scientists detect two decision-making pathways in human brain
9. Concerns about fertility affect treatment decisions in one-third of young breast cancer patients
10. Women pleased with preventative mastectomy decision
11. Exercise sharpens focus, decision-making among aging adults

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OTC statins bad decision for public health

(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care ... the chaos that can occur for people who have ... of Americans who come into the emergency department facing ... for the moment and so are their families." She ... a catalyst for a family to get the critical ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: